Antipsoriatic Drug Discovery Services
The complexity of psoriasis stems from its multifaceted etiology, including genetic predispositions and immune system dysregulations. This disease is driven by a complex interplay between genetic, immunological, and environmental factors, with the IL-23/Th17/IL-17 axis playing a pivotal role in its pathogenesis. Despite the availability of various therapeutic strategies, there remains a significant unmet need for more effective and safer antipsoriatic therapies.
Ongoing research in the field has focused on exploring novel drug targets, optimizing drug delivery methods, and developing combination therapies to improve therapeutic efficiency. At Ace Therapeutics, we offer a comprehensive suite of services to support researchers and pharmaceutical companies in the development of innovative antipsoriatic drugs.
Our antipsoriatic drug discovery services span a diverse range of drug modalities, allowing us to tailor our approach to your specific research needs. From small molecules to peptide-based therapies, we have the expertise to support the development of a wide variety of antipsoriatic therapeutics.
Antipsoriatic Small Molecules
Leveraging our expertise in medicinal chemistry and high-throughput screening, we offer comprehensive services for the discovery and optimization of antipsoriatic small molecule candidates. From hit identification to lead optimization, we are dedicated to supporting our clients uncovering novel pharmacological targets and developing potent small molecule therapeutics.
Antipsoriatic Therapeutic Antibody
Recognizing the power of biologics in the treatment of complex inflammatory diseases, we provide end-to-end services for the development of antipsoriatic antibodies. Our capabilities span the entire spectrum, from target identification and antibody discovery to production, characterization, and preclinical evaluation.
Antipsoriatic Peptides
Peptides have emerged as a promising class of antipsoriatic agents, offering unique advantages in terms of specificity, safety, and enhanced delivery. We provide comprehensive antipsoriatic peptide development services, using peptide engineering and optimization techniques to accelerate the development of novel therapeutic candidates.
Nucleic Acid-Based Antipsoriatic Therapy
Harnessing the transformative potential of nucleic acid-based interventions, we offer comprehensive services for the development of both DNA-based and RNA-based antipsoriatic therapies. Our multidisciplinary team specializes in vector design, gene delivery optimization, and preclinical evaluation to bring forth gene-based solutions for our clients.
Targeting the underlying pathways and mediators of psoriasis is crucial for the development of effective therapeutics. Ace Therapeutics provides customized antipsoriatic drug development services from initial target identification and assay development to preclinical testing. Our comprehensive suite of services is designed to accelerate the discovery and optimization of novel antipsoriatic drug candidates.
Optimizing the delivery of antipsoriatic drugs is essential to advance their therapeutic potential. Our specialized services cover a range of administration routes, enabling us to provide comprehensive drug development services to meet your specific needs.
Topical Antipsoriatics
4.9 Topical therapies have long been the foundation of psoriasis treatment, as they directly target the affected areas with minimal systemic exposure. Ace Therapeutics provides preclinical services that encompass formulation development, in vitro and in vivo efficacy testing, and safety evaluations to support your projects.
Subcutaneous Antipsoriatic Therapies
Subcutaneous administration offers targeted delivery with controlled release, improving therapeutic efficacy and compliance. Ace Therapeutics offers a comprehensive range of subcutaneous antipsoriatic therapy development services to support our clients in designing and optimizing injectable therapeutic candidates.
Systemic Antipsoriatic Drugs
Systemic antipsoriatic therapies play a crucial role in managing moderate to severe psoriasis, providing widespread efficacy through targeting systemic immune responses. Ace Therapeutics offers comprehensive systemic antipsoriatic drug development services to support our clients in the discovery and optimization of orally administered or intravenously delivered antipsoriatic drugs.
Psoriasis is not a single disease, but rather a collection of skin diseases, each with its own unique characteristics. At Ace Therapeutics, we recognize the the significance of addressing the specific characteristics of each psoriasis subtype, and we provide specialized drug development services to cater to these unique needs.
Plaque Psoriasis
Plaque psoriasis is characterized by well-defined, red, scaly plaques on the skin, resulting from an overactive immune response. Research in this area has evolved rapidly, focusing on understanding the molecular mechanisms driving inflammation, keratinocyte proliferation, and the development of innovative biologics and small molecules that target specific pathways. The IL-23/Th17 axis has emerged as a central pathogenic pathway in plaque psoriasis, making it a prime target for therapeutic intervention.
At Ace Therapeutics, we provide a suite of services aimed at understanding the molecular underpinnings of plaque psoriasis. Our services encompass target identification, high-throughput screening, and efficacy studies geared toward discovering novel therapies. Our workflow is designed to streamline drug discovery, providing a robust preclinical foundation for your drug development projects.
Guttate Psoriasis
Guttate psoriasis often manifests suddenly, triggered by infections or stress, and is particularly prevalent in younger populations. This acute form is characterized by the sudden appearance of small, drop-like lesions, primarily on the trunk and limbs. Current research is focused on understanding the immunological triggers and genetic predispositions that lead to this disease.
At Ace Therapeutics, our services for guttate psoriasis focus on identifying and characterizing the immunological triggers and the subsequent inflammatory response. We specialize in supporting the development of targeted therapies with a focus on the unique pathophysiological mechanisms that drivie this subtype. Our comprehensive services encompasses in-depth immunological profiling and the design of tailored drug delivery systems for guttate psoriasis.
Erythrodermic Psoriasis
Erythrodermic psoriasis is a severe disease characterized by extensive redness and scaling of the skin with systemic symptoms. This disease can be life-threatening and requires immediate and effective therapeutic intervention. Current research efforts are directed at developing therapeutic strategies that can quickly manage systemic inflammation and restore skin barrier function.
Ace Therapeutics provides tailored services to assist in the development of therapeutics for erythrodermic psoriasis. Our services are designed to support the rapid progression of drug candidates through preclinical stages. Our expertise includes identifying and testing therapies that target the systemic inflammatory response and help stabilize the disease.
Pustular Psoriasis
Pustular psoriasis is characterized by white pustules surrounded by red skin and can be either localized or generalized. This disease often comes with systemic symptoms and involves complex inflammatory mechanisms. Current research is focused on targeting these mechanisms to prevent pustule formation and control systemic inflammation.
We provide comprehensive support for the development of therapeutics targeting pustular psoriasis. Our services span from early-stage target identification to preclinical validation, assisting you in thoroughly testing and optimizing your therapeutic candidates against this challenging disease.
Annular Psoriasis
Annular psoriasis is a rare and distinctive subtype of the disease, characterized by the development of circular or ring-shaped lesions on the skin. These lesions can appear on various parts of the body, often with a clearing center and a raised, scaly border. Given the rarity of annular psoriasis, research in this area has been limited. Ongoing studies are exploring targeted therapies, combination approaches, and novel formulations.
At Ace Therapeutics, we are dedicated to supporting the development of innovative therapeutics for annular psoriasis. Our comprehensive preclinical services include the evaluation of custom animal models, assessment of drug candidates, evaluation of drug resistance, exploration of combination strategies, and formulation development.
Psoriatic Arthritis
Psoriatic arthritis is a complex disease characterized by the co-occurrence of psoriasis and inflammatory arthritis. Considerable research efforts are focused on understanding the complex interplay between the skin and joint manifestations of psoriatic arthritis, as well as developing more effective and targeted therapeutic options that can halt disease progression and improve joint function.
Ace Therapeutics is dedicated to supporting the development of innovative therapies for this challenging disease. We provide comprehensive services to support the development and evaluation of disease-relevant models, such as mannan-induced psoriatic arthritis models. Our services encompass the comprehensive assessment of the impact of drug candidates on joint and skin pathology, exploration of combination therapies, and optimization of systemic drug delivery approaches.
